Blood- and Imaging-Derived Biomarkers for Oncological Outcome Modelling in Oropharyngeal Cancer: Exploring the Low-Hanging Fruit

Author:

Volpe Stefania12,Gaeta Aurora3ORCID,Colombo Francesca12,Zaffaroni Mattia1ORCID,Mastroleo Federico14ORCID,Vincini Maria Giulia1ORCID,Pepa Matteo1ORCID,Isaksson Lars Johannes1,Turturici Irene1,Marvaso Giulia12ORCID,Ferrari Annamaria1,Cammarata Giulio3,Santamaria Riccardo12,Franzetti Jessica12,Raimondi Sara3ORCID,Botta Francesca5ORCID,Ansarin Mohssen6,Gandini Sara3ORCID,Cremonesi Marta7,Orecchia Roberto8,Alterio Daniela1,Jereczek-Fossa Barbara Alicja12

Affiliation:

1. Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Via Ripamonti, 435, 20141 Milan, Italy

2. Department of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, Italy

3. Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy

4. Department of Translational Medicine, University of Piemonte Orientale (UPO), 28100 Novara, Italy

5. Medical Physics Unit, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy

6. Division of Division of Otolaryngology and Head and Neck Surgery, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy

7. Radiation Research Unit, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy

8. Scientific Directorate, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy

Abstract

Aims: To assess whether CT-based radiomics and blood-derived biomarkers could improve the prediction of overall survival (OS) and locoregional progression-free survival (LRPFS) in patients with oropharyngeal cancer (OPC) treated with curative-intent RT. Methods: Consecutive OPC patients with primary tumors treated between 2005 and 2021 were included. Analyzed clinical variables included gender, age, smoking history, staging, subsite, HPV status, and blood parameters (baseline hemoglobin levels, neutrophils, monocytes, and platelets, and derived measurements). Radiomic features were extracted from the gross tumor volumes (GTVs) of the primary tumor using pyradiomics. Outcomes of interest were LRPFS and OS. Following feature selection, a radiomic score (RS) was calculated for each patient. Significant variables, along with age and gender, were included in multivariable analysis, and models were retained if statistically significant. The models’ performance was compared by the C-index. Results: One hundred and five patients, predominately male (71%), were included in the analysis. The median age was 59 (IQR: 52–66) years, and stage IVA was the most represented (70%). HPV status was positive in 63 patients, negative in 7, and missing in 35 patients. The median OS follow-up was 6.3 (IQR: 5.5–7.9) years. A statistically significant association between low Hb levels and poorer LRPFS in the HPV-positive subgroup (p = 0.038) was identified. The calculation of the RS successfully stratified patients according to both OS (log-rank p < 0.0001) and LRPFS (log-rank p = 0.0002). The C-index of the clinical and radiomic model resulted in 0.82 [CI: 0.80–0.84] for OS and 0.77 [CI: 0.75–0.79] for LRPFS. Conclusions: Our results show that radiomics could provide clinically significant informative content in this scenario. The best performances were obtained by combining clinical and quantitative imaging variables, thus suggesting the potential of integrative modeling for outcome predictions in this setting of patients.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference52 articles.

1. Performance/outcomes data and physician process challenges for practical big data efforts in radiation oncology;Matuszak;Med. Phys.,2018

2. A review on the advances and challenges of immunotherapy for head and neck cancer;Cheng;Cancer Cell Int.,2021

3. NCCN (2023, January 24). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Head and Neck Cancers [Internet]. Available online: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf.

4. An Update on the Immunotherapy for Oropharyngeal Squamous Cell Carcinoma;Huang;Front. Oncol.,2022

5. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): A randomised, open-label, phase 3 study;Cohen;Lancet,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3